drug
teriflunomide
Marketedupdated 3mo agoby SOLA Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- drugAUBAGIO29 co-mentions · 15 sources
- tagApproval28 co-mentions · 14 sources
- company$SNYSanofi14 co-mentions · 14 sources
- company$SNYNFSanofi14 co-mentions · 14 sources
- tagSmall Molecule14 co-mentions · 14 sources
- companyGlenmark Pharmaceuticals Ltd3 co-mentions · 1 sources
- tagRecall1 co-mentions · 1 sources
all catalysts(14)
approval · 14
Sep 12, 2012
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Oct 17, 2014
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Jun 2, 2016
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Nov 29, 2016
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Dec 19, 2017
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Jul 24, 2019
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Sep 6, 2019
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Feb 28, 2020
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Nov 6, 2020
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Nov 6, 2020
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Apr 30, 2021
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Apr 30, 2021
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Jun 10, 2024
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Feb 11, 2026
approval
AUBAGIO (TERIFLUNOMIDE) — FDA approval
teriflunomide
→
Trials studying teriflunomide
- phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
- phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- —A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- phase3Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- phase3Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- phase3A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- phase4Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 12, 2026
22 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Aug 4, 2034patentUS 9186346*PED
- Aug 4, 2034patentUS 9186346*PED
- Feb 4, 2034method-of-use (U-1786)US 9186346
- Feb 4, 2034method-of-use (U-1786)US 9186346
- Mar 14, 2031patentUS 8802735*PED4.6y
- Mar 14, 2031patentUS 8802735*PED4.6y
- Sep 14, 2030formulationUS 88027354.1y
- Sep 14, 2030formulationUS 88027354.1y
- Mar 12, 2027patentUS 6794410*PED203d
- Mar 12, 2027patentUS 6794410*PED203d
- Sep 12, 2026method-of-use (U-1285)US 679441022d
- Sep 12, 2026method-of-use (U-1285)US 679441022d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that